CY1120911T1 - Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα - Google Patents

Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα

Info

Publication number
CY1120911T1
CY1120911T1 CY181101058T CY181101058T CY1120911T1 CY 1120911 T1 CY1120911 T1 CY 1120911T1 CY 181101058 T CY181101058 T CY 181101058T CY 181101058 T CY181101058 T CY 181101058T CY 1120911 T1 CY1120911 T1 CY 1120911T1
Authority
CY
Cyprus
Prior art keywords
mdck
serum
produced
culture
mdck cell
Prior art date
Application number
CY181101058T
Other languages
English (en)
Inventor
Yong Wook Park
Kun Se Lee
Bong-Yong Lee
Mahnhoon Park
Hun Kim
Yun-Hee Kim
Su-Jeen Lee
Original Assignee
Sk Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Bioscience Co Ltd filed Critical Sk Bioscience Co Ltd
Publication of CY1120911T1 publication Critical patent/CY1120911T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε MDCK κυτταρική σειρά η οποία παράγεται από MDCK κύτταρο κατατεθειμένο ως ATCC CCL-34 κυτταρική σειρά και μπορεί να καλλιεργηθεί χωρίς ορό και μπορεί να είναι καλλιεργημένο εναιώρημα και κατά προτίμηση σε κυτταρικές σειρές MDCK S1023, MDCK S10234 και MDCK S3851. Επιπλέον, η παρούσα εφεύρεση αφορά σε μέθοδο καλλιέργειας για ανάπτυξη του MDCK κυττάρου και μέθοδο για παρασκευή ιών για εμβόλια χρησιμοποιώντας το MDCK κύτταρο.
CY181101058T 2010-09-06 2018-10-16 Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα CY1120911T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/KR2010/006041 WO2012033236A1 (ko) 2010-09-06 2010-09-06 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
KR1020110085902A KR20120024464A (ko) 2010-09-06 2011-08-26 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
PCT/KR2011/006589 WO2012033328A2 (en) 2010-09-06 2011-09-06 Mdck-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells

Publications (1)

Publication Number Publication Date
CY1120911T1 true CY1120911T1 (el) 2019-12-11

Family

ID=45810820

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101058T CY1120911T1 (el) 2010-09-06 2018-10-16 Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα

Country Status (19)

Country Link
US (2) US20130183741A1 (el)
EP (1) EP2614140B8 (el)
JP (1) JP6067560B2 (el)
KR (2) KR20120024464A (el)
CN (2) CN103154238A (el)
AU (1) AU2011299761B2 (el)
BR (1) BR112013005298A2 (el)
CY (1) CY1120911T1 (el)
DK (1) DK2614140T3 (el)
ES (1) ES2695044T3 (el)
HR (1) HRP20181422T1 (el)
HU (1) HUE040534T2 (el)
LT (1) LT2614140T (el)
PL (1) PL2614140T3 (el)
PT (1) PT2614140T (el)
RS (1) RS57656B1 (el)
SI (1) SI2614140T1 (el)
TR (1) TR201815631T4 (el)
WO (2) WO2012033236A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2012033236A1 (ko) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
JP6152535B2 (ja) * 2012-04-16 2017-06-28 公益財団法人ヒューマンサイエンス振興財団 細胞培養組成物及びインフルエンザウイルスの生産方法
CN104059873B (zh) * 2013-03-20 2016-09-28 上海生物制品研究所有限责任公司 用于扩增流感病毒的非致瘤性mdck细胞系及其筛选方法
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
CN104726392B (zh) * 2013-12-18 2018-09-28 普莱柯生物工程股份有限公司 一种制备无血清培养的悬浮哺乳动物细胞系的方法、及其制备的细胞系和应用
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US10786564B2 (en) * 2015-10-30 2020-09-29 National Health Research Institutes MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
CN107460156B (zh) * 2016-06-03 2022-03-11 兆丰华生物科技(南京)有限公司北京生物医药科技中心 无血清全悬浮mdck细胞株及其在生产流感病毒中的应用
CN105861422B (zh) * 2016-06-24 2019-05-24 肇庆大华农生物药品有限公司 一种适应无血清全悬浮培养的mdck细胞系的制备方法及通过该制备方法获得的mdck细胞系
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
CN106884003A (zh) * 2017-01-22 2017-06-23 西北民族大学 无成瘤性mdck细胞克隆株
CN106801031A (zh) * 2017-01-22 2017-06-06 西北民族大学 无成瘤性mdck细胞克隆株
KR101831284B1 (ko) * 2017-06-26 2018-02-22 에스케이케미칼 주식회사 무혈청 배지에서 부유배양 되는 Vero 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
KR102453351B1 (ko) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
CN108277199B (zh) * 2018-01-17 2021-06-25 武汉生物制品研究所有限责任公司 广谱低致瘤性mdck细胞系及其应用
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN109852579A (zh) * 2019-03-27 2019-06-07 西北民族大学 无血清悬浮培养型mdck细胞株及其应用
CN109852580A (zh) * 2019-03-27 2019-06-07 西北民族大学 无血清悬浮培养型mdck细胞株及其应用
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
CN110669722A (zh) * 2019-10-23 2020-01-10 长春生物制品研究所有限责任公司 一种用于mdck细胞的无血清全悬浮驯化方法
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
JP2023524015A (ja) 2020-04-29 2023-06-08 エスケー バイオサイエンス カンパニー リミテッド 使い捨て培養工程システムを用いたインフルエンザウイルス生産方法及びインフルエンザウイルス抗原精製条件の迅速確認試験
CN112195148B (zh) * 2020-08-17 2023-01-03 上海生物制品研究所有限责任公司 无血清悬浮适应的mdck细胞及其在制备流感病毒疫苗中的应用
CN112410305A (zh) * 2020-11-26 2021-02-26 中国医学科学院病原生物学研究所 一种高产的流感病毒制备体系及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3604201A (en) * 2000-03-03 2001-09-12 Chemo Sero Therapeut Res Inst Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
JP5414178B2 (ja) * 2004-12-23 2014-02-12 メディミューン，エルエルシー ウイルス増殖用の非腫瘍形成性ｍｄｃｋ細胞株
AU2007297178B2 (en) * 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
CN102216450B (zh) * 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
WO2012033236A1 (ko) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법

Also Published As

Publication number Publication date
EP2614140A4 (en) 2014-03-05
RS57656B1 (sr) 2018-11-30
JP6067560B2 (ja) 2017-01-25
AU2011299761A1 (en) 2013-03-21
KR20150056519A (ko) 2015-05-26
EP2614140B1 (en) 2018-08-08
EP2614140B8 (en) 2018-10-17
CN104862267A (zh) 2015-08-26
WO2012033328A2 (en) 2012-03-15
US20150247128A1 (en) 2015-09-03
PL2614140T3 (pl) 2019-02-28
PT2614140T (pt) 2018-11-22
KR101577745B1 (ko) 2015-12-16
CN103154238A (zh) 2013-06-12
JP2013540431A (ja) 2013-11-07
WO2012033328A3 (en) 2012-06-28
US9447383B2 (en) 2016-09-20
HRP20181422T1 (hr) 2018-10-19
TR201815631T4 (tr) 2018-11-21
CN104862267B (zh) 2019-07-12
LT2614140T (lt) 2018-10-25
AU2011299761B2 (en) 2017-01-05
ES2695044T3 (es) 2018-12-28
KR20120024464A (ko) 2012-03-14
WO2012033236A1 (ko) 2012-03-15
BR112013005298A2 (pt) 2020-01-07
DK2614140T3 (en) 2018-10-22
EP2614140A2 (en) 2013-07-17
HUE040534T2 (hu) 2019-03-28
SI2614140T1 (sl) 2018-11-30
US20130183741A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
CY1120911T1 (el) Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
BR112017011582A2 (pt) fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
MX361139B (es) Mutantes de virus de influenza y usos para los mismos.
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
NZ596880A (en) Production of polio virus at high titers for vaccine production
PH12017501445A1 (en) Methods for producing virus for vaccine production
CY1116835T1 (el) Νεο ευρωπαϊκο στελεχος toy prrsv
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MY161891A (en) Virus like particle production in plants
MX2021009554A (es) Produccion de virus en cultivos celulares.
MX358762B (es) Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
MX2018006386A (es) Produccion de virus en evos aviares.
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
MX366836B (es) Celulas aviares para la produccion mejorada de virus.
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
MX363464B (es) Vacunas contra influenza h5.
EA201100902A1 (ru) Новый способ получения рнк-вируса
WO2012069190A3 (en) Depletion of host cell components from live virus vaccines
BR112015021772A2 (pt) método para a preparação de células embrionárias aviárias, método melhorado para a preparação de células embrionárias aviárias a partir de um embrião, cultura ou composição de células embrionárias aviárias, método para a produção ou amplificação de um vírus, e, composição de vacina
MY188494A (en) High-growth enterovirus 71 strains and vaccines
EA201201620A1 (ru) Способ получения рнк-вируса
WO2013093512A3 (en) Vaccine - screening method